Sathe Nila A, Krishnaswami Shanthi, Andrews Jeff, Ficzere Cathy, McPheeters Melissa L
Vanderbilt Evidence-based Practice Center, Institute for Medicine and Public Health Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee.
Vanderbilt Evidence-based Practice Center, Institute for Medicine and Public Health.
Respir Care. 2015 Jul;60(7):1061-70. doi: 10.4187/respcare.04086. Epub 2015 May 5.
Pharmacologic agents to promote mucus clearance may reduce the sequelae of obstructive secretions. We systematically reviewed comparative studies of pharmacologic agents for mucus clearance in hospitalized or postoperative subjects without cystic fibrosis and over 12 months of age. We searched MEDLINE and other databases from January 1970 to July 2014 to identify relevant literature. Two reviewers independently assessed each study against predetermined inclusion/exclusion criteria. Two reviewers also independently extracted data regarding subject and intervention characteristics and outcomes and assigned overall quality ratings. The 9 studies meeting review criteria included 5 randomized controlled trials, 3 crossover randomized controlled trials, and one retrospective cohort study. Studies were small and together included a total of 379 subjects (mean of 42 subjects per study). N-acetylcysteine, heparin plus N-acetylcysteine, albuterol, ipratropium bromide, and saline were assessed. Studies reported no benefit of studied agents on expectoration, pulmonary function, and atelectasis and little effect on changes in sputum volume, weight, or viscosity. Adverse effects of agents were not consistently reported. Nausea was reported in 2 studies of N-acetylcysteine (one paper reported 2 experiments and did not clearly identify in which experiment adverse effects occurred), 3 studies reported that there were no adverse events, and 3 studies did not address adverse effects at all. Further research with clearly characterized populations and interventions is needed to understand the potential benefits and adverse effects of mucoactive agents.
促进黏液清除的药物制剂可能会减少阻塞性分泌物的后遗症。我们系统回顾了针对12个月以上非囊性纤维化的住院患者或术后患者使用药物制剂促进黏液清除的比较研究。我们检索了1970年1月至2014年7月期间的MEDLINE及其他数据库,以确定相关文献。两名审阅者根据预先确定的纳入/排除标准独立评估每项研究。两名审阅者还独立提取了有关受试者、干预措施特征及结果的数据,并给出总体质量评级。符合审阅标准的9项研究包括5项随机对照试验、3项交叉随机对照试验和1项回顾性队列研究。这些研究规模较小,总共纳入了379名受试者(每项研究平均42名受试者)。对N-乙酰半胱氨酸、肝素加N-乙酰半胱氨酸、沙丁胺醇、异丙托溴铵和生理盐水进行了评估。研究报告称,所研究的药物制剂在排痰、肺功能和肺不张方面没有益处,对痰液量、重量或黏稠度的变化影响也很小。药物的不良反应报告并不一致。在两项关于N-乙酰半胱氨酸的研究中报告了恶心(一篇论文报告了2项实验,未明确指出不良反应发生在哪项实验中),3项研究报告没有不良事件,3项研究根本未涉及不良反应。需要针对特征明确的人群和干预措施开展进一步研究,以了解黏液活性药物的潜在益处和不良反应。